Risk Factors Update Summary
- Addition of LOQTORZI to the product portfolio facing significant competition in the oncology market.
- Sales of common stock increased from 78 million to 112 million shares outstanding.
- Accumulated deficit increased from $1.3 billion to $1.6 billion, indicating continued losses.
- Minimum net sales requirement decreased from $300 million to $125 million.
- Launch of YUSIMRY in July 2023 may face competition from AbbVie, impacting sales.
- The initial conversion price changed from $19.26 to $51.9224 per share.
- Potential delays in clinical trials due to patient enrollment challenges may affect development timelines.
- Introduction of the IRA law may significantly impact the pharmaceutical industry's pricing and profitability.
- Inclusion of new models by HHS for drug cost reduction, affecting future health reform measures.
- Potential implications of the 340B ceiling price and civil penalties on manufacturers for overcharging.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1512762&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.